Drug Type Bispecific T-cell Engager (BiTE) |
Synonyms- |
Target |
Action stimulants, antagonists |
Mechanism CD3 stimulants(T cell surface glycoprotein CD3 stimulants), CDH17 antagonists(Cadherin-17 antagonists) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhasePendingPreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Colonic Cancer | Preclinical | United States | 01 Jul 2018 |